Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYGR Voyager Therapeutics

Pre-Mkt 03-16 06:54:53 EDT

4.46

-0.41

-8.52%

High4.91	Low4.35	Vol1.03M
Open4.85	D1 Closing4.87	Amplitude11.50%
Mkt Cap265.52M	Tradable Cap210.80M	Total Shares59.60M
T/O4.65M	T/O Rate2.17%	Tradable Shares47.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VYGR","market":"US","secType":"STK","nameCN":"Voyager Therapeutics","latestPrice":4.455,"timestamp":1773432000000,"preClose":4.87,"halted":0,"volume":1028716,"delay":0,"changeRate":-0.08521560574948665,"floatShares":47318300,"shares":59599375,"eps":-2.039999,"marketStatus":"Pre-Mkt","change":-0.415,"latestTime":"03-16 06:54:53 EDT","open":4.85,"high":4.91,"low":4.3501,"amount":4647835.1758176,"amplitude":0.114969,"askPrice":5.26,"askSize":100,"bidPrice":3.87,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.039999,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773667800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1447218000000,"exchange":"NASDAQ","adjPreClose":4.455,"postHourTrading":{"tag":"盘后","latestPrice":4.54,"preClose":4.455,"latestTime":"19:55 EDT","volume":312,"amount":1436.5208,"timestamp":1773446104895,"change":0.085,"changeRate":0.01908,"amplitude":0.01908},"volumeRatio":0.5652899354794254,"impliedVol":0.5264,"impliedVolPercentile":0.18},"requestUrl":"/m/hq/s/VYGR","defaultTab":"news","newsList":[{"id":"2618792003","title":"Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2618792003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618792003?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:45","pubTimestamp":1773254723,"startTime":"0","endTime":"0","summary":"Analyst Yun Zhong of Wedbush maintained a Buy rating on Voyager Therapeutics, with a price target of $8.00. Yun Zhong has given his Buy rating due ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-advancing-tau-targeted-gene-therapy-with-multiple-near-term-catalysts-and-attractive-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-advancing-tau-targeted-gene-therapy-with-multiple-near-term-catalysts-and-attractive-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2618413249","title":"Guggenheim Remains a Buy on Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618413249?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:17","pubTimestamp":1773227827,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating on Voyager Therapeutics yesterday and set a price target of $22.00. The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2618991384","title":"Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2618991384","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618991384?lang=en_us&edition=fundamental","pubTime":"2026-03-11 14:01","pubTimestamp":1773208912,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. (VYGR) has disclosed a new risk, in the Capital Markets category. Voyager Therapeutics Inc. faces heightened exposure to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-faces-rising-tariff-and-u-s-china-geopolitical-risks-as-biosecure-act-threatens-key-chinese-cdmo-partnerships?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-faces-rising-tariff-and-u-s-china-geopolitical-risks-as-biosecure-act-threatens-key-chinese-cdmo-partnerships?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CDMO","VYGR"],"gpt_icon":0},{"id":"2618308739","title":"Voyager Therapeutics: Undervalued Neurology Pipeline With High‑Reward 2026 Catalysts Supports Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618308739","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618308739?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143726,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sumant Kulkarni from Canaccord Genuity m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-undervalued-neurology-pipeline-with-high‑reward-2026-catalysts-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-undervalued-neurology-pipeline-with-high‑reward-2026-catalysts-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2618346089","title":"Voyager Therapeutics: 2026 Tau Data Catalysts and Gene Therapy Milestones Support Buy/High Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618346089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618346089?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:56","pubTimestamp":1773140187,"startTime":"0","endTime":"0","summary":"In a report released today, Samantha Semenkow from Citi maintained a Buy rating on Voyager Therapeutics, with a price target of $11.00. Samantha Se...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-2026-tau-data-catalysts-and-gene-therapy-milestones-support-buy-high-risk-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-2026-tau-data-catalysts-and-gene-therapy-milestones-support-buy-high-risk-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2618931926","title":"Voyager Therapeutics (VYGR) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618931926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618931926?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:35","pubTimestamp":1773138933,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target of $25.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/voyager-therapeutics-vygr-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/voyager-therapeutics-vygr-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2618608425","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and West Pharmaceutical Services (WST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618608425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618608425?lang=en_us&edition=fundamental","pubTime":"2026-03-10 07:00","pubTimestamp":1773097240,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report) and We...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-west-pharmaceutical-services-wst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-west-pharmaceutical-services-wst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WST","LU0345774631.USD","HCSG","BK4585","XBI","IE00BYQQ9H92.USD","BK4137","BK4139","LU0029874061.USD","BK4588","LU0345774391.USD","LU0106261612.USD","LABU","IE00B64QTZ34.USD","VYGR","IE00BFXG0V08.USD","LU0128526141.USD","BK4504","BK4567","BK4121","BK4581","LU0012050646.USD","XLV"],"gpt_icon":0},{"id":"2618672798","title":"Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672798","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672798?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:55","pubTimestamp":1773089743,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryVoyager Therapeutics Inc VYGR.OQ reported a quarterly adjusted loss of 46 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL8N3ZX2F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2618209674","title":"Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618209674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618209674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:10","pubTimestamp":1773087045,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $15.34M, consensus $10.49M. “Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year defined by thr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-reports-q4-eps-46c-consensus-51c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-reports-q4-eps-46c-consensus-51c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2618367108","title":"Voyager Therapeutics Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618367108","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618367108?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086511,"startTime":"0","endTime":"0","summary":"Voyager reported Q4 collaboration revenue of USD 15.34 million, up 144%, driven mainly by higher revenue recognized under its Neurocrine agreement. Q4 net loss was USD 27.43 million, while R&D expenses were USD 35.95 million and G&A expenses were USD 9.32 million. For FY2025, collaboration revenue was USD 40.37 million, down 50% due mainly to higher collaboration revenue recognized in FY2024 tied to the Neurocrine and Novartis agreements, and net loss was USD 119.72 million. Voyager ended FY2025 with cash, cash equivalents and marketable securities of USD 201.69 million and said it expects its cash runway to extend into 2028. Management said 2026 priorities include first-in-human dosing of its tau-silencing gene therapy VY1706 in H2 2026 and tau PET imaging data from the VY7523 Alzheimer’s MAD trial in H2 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL9qYNDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE00B3QW5Z07.USD","LU0154245673.USD","SG9999014005.SGD","LU2210150020.SGD","NBIX","IE00BGHQF748.EUR","LU0154245756.USD","LU2324357040.USD","BK4112","BK4585","SG9999014013.SGD","LU2065170008.USD","LU2210149790.SGD","SG9999014021.USD","LU2065171402.SGD","BK4588","NDAQ","IE00BKPKM429.USD","LU0823416689.USD","LU0320765992.SGD","LU2095319765.USD","LU0314104364.USD","LU2065171311.SGD","LU2065169927.USD","LU0109394709.USD","SG9999014039.USD","IE00B64PRP62.GBP","VYGR","BK4139"],"gpt_icon":0},{"id":"2618710366","title":"BRIEF-Voyager Therapeutics Q4 EPS USD -0.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2618710366","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618710366?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086505,"startTime":"0","endTime":"0","summary":"BRIEF-Voyager Therapeutics Q4 EPS USD -0.46\n\n\nMar 09 (Reuters) - Voyager Therapeutics Q4 basic EPS USD -0.47.\n\nQ4 net income USD -27.426 million\nQ4 collaboration revenue USD 15.336 million\nQ4 operating income USD -29.932 million\nQ4 pretax profit USD -27.417 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLX4EAB82:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2618671730","title":"Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618671730?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUAFJ2LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2618006671","title":"Voyager Therapeutics Inc: Ended 2025 With Cash Position of $202 Million, Expected to Maintain Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2618006671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618006671?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLX4EAB82:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2617684132","title":"Voyager Therapeutics Inc  expected to post a loss of 51 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617684132","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617684132?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:11","pubTimestamp":1772795464,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc  expected to post a loss of51cents a share - Earnings Preview Voyager Therapeutics Inc VYGR.OQ VYGR.O is expected to  show a rise in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU0Y4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2610929571","title":"Voyager Therapeutics Chief Medical Officer Toby Ferguson Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929571","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929571?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:02","pubTimestamp":1770901330,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. announced that Chief Medical Officer Toby Ferguson, M.D., Ph.D., will resign from his position effective February 20, 2026, to pursue a new opportunity. Following his departure, President and CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will assume key responsibilities for the company’s clinical development programs on an interim basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLbRsLKc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2610296922","title":"Voyager Therapeutics CEO Alfred Sandrock Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2610296922","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610296922?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:31","pubTimestamp":1770845500,"startTime":"0","endTime":"0","summary":"Alfred Sandrock, President and CEO of Voyager Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL920m5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Voyager Therapeutics CEO Alfred Sandrock Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2610365847","title":"Voyager Therapeutics to Present at Multiple Major Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2610365847","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610365847?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:01","pubTimestamp":1770642095,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL7V3qYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014013.SGD","LU2210150020.SGD","BK4588","SG9999014005.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","SG9999014021.USD","VYGR"],"gpt_icon":0},{"id":"2609391777","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609391777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609391777?lang=en_us&edition=fundamental","pubTime":"2026-02-05 01:30","pubTimestamp":1770226221,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report), Infla...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-inflarx-ifrx-and-verastem-vstm-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-inflarx-ifrx-and-verastem-vstm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4137","HCSG","XBI","BK4588","VSTM","BK4581","BK4585","IFRX","LU0029874061.USD","VYGR","BK4139","LABU","XLV"],"gpt_icon":0},{"id":"2602316207","title":"Voyager Therapeutics Files Initial Beneficial Ownership Statement for Gregory L. Shiferman, SVP and General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2602316207","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602316207?lang=en_us&edition=fundamental","pubTime":"2026-01-09 07:08","pubTimestamp":1767913724,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Gregory L. Shiferman, who serves as Senior Vice President and General Counsel, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL7w9qMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Voyager Therapeutics Files Initial Beneficial Ownership Statement for Gregory L. Shiferman, SVP and General Counsel","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2583304326","title":"Voyager Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2583304326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583304326?lang=en_us&edition=fundamental","pubTime":"2025-11-13 02:55","pubTimestamp":1762973700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 13:55 ET (18:55 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.voyagertherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1423},{"period":"1month","weight":0.2205},{"period":"3month","weight":0.0148},{"period":"6month","weight":0.0658},{"period":"1year","weight":0.0959},{"period":"ytd","weight":0.1336}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.004281},{"month":2,"riseRate":0.545455,"avgChangeRate":0.057874},{"month":3,"riseRate":0.545455,"avgChangeRate":0.05109},{"month":4,"riseRate":0.5,"avgChangeRate":0.019214},{"month":5,"riseRate":0.6,"avgChangeRate":0.041264},{"month":6,"riseRate":0.5,"avgChangeRate":0.010419},{"month":7,"riseRate":0.4,"avgChangeRate":-0.019026},{"month":8,"riseRate":0.6,"avgChangeRate":-0.020662},{"month":9,"riseRate":0.2,"avgChangeRate":0.071458},{"month":10,"riseRate":0.3,"avgChangeRate":-0.010359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.07862},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.036226}],"exchange":"NASDAQ","name":"Voyager Therapeutics","nameEN":"Voyager Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Voyager Therapeutics,VYGR,Voyager Therapeutics股票,Voyager Therapeutics股票老虎,Voyager Therapeutics股票老虎国际,Voyager Therapeutics行情,Voyager Therapeutics股票行情,Voyager Therapeutics股价,Voyager Therapeutics股市,Voyager Therapeutics股票价格,Voyager Therapeutics股票交易,Voyager Therapeutics股票购买,Voyager Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction